pentobarbital will decrease the level or outcome of buprenorphine subdermal implant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Check patients previously on buprenorphine subdermal implant who have to have newly-initiated remedy with CYP3A4 inducer for signs and signs or symptoms of withdrawal.
pentobarbital will reduce the level or effect of alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will decrease the level or outcome of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
Contraindicated (1)pentobarbital will minimize the level or result of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration. Potent or moderate CYP3A inducers may possibly minimize cobimetinib systemic exposure by >80% and lower its efficacy.
pentobarbital will decrease the level or result of bexarotene by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will minimize the level or influence of erlotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will minimize the extent or outcome of flurbiprofen by impacting hepatic enzyme CYP2C9/ten metabolism. Small/Importance Unknown.
pentobarbital will lower the level or outcome of ziprasidone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.
pentobarbital will decrease the extent or influence of maraviroc by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Contraindicated (one)pentobarbital will decrease the level or impact of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lessen the level or effect of avanafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. For patients with ED, check response cautiously read more on account of possible for reduced effectiveness.
Contraindicated (1)pentobarbital will minimize the extent or effect of naloxegol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Use of naloxegol with sturdy CYP3A4 inducers is just not recommended
pentobarbital will reduce the level or influence of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.
pentobarbital will lower the level or effect of finasteride by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.